Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,466.6490 pence per share.
Material Changes
On April 18, 2007, the Company purchased 600,000 Ordinary shares of 25 pence each. Following this transaction, the total number of shares held in Treasury increased to 287,342,678. The number of shares in issue (excluding Treasury shares) stands at 5,728,124,515, which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total Treasury share count of 287,342,678 against subsequent filings.
- Confirm the total voting rights denominator of 5,728,124,515 for disclosure threshold calculations.
- Review the Annual General Meeting minutes from May 17, 2006, to confirm the scope of the share repurchase authority.